Exhibit 99.1 istol Myers Squibb® Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth • Third Quarter Revenues were $11.9 Billion, increasing 8% (+10% Adjusting for Foreign Exchange) • Growth Portfolio Revenues were $5.8 Billion, increasing 18% (+20% Adjusting for Foreign Exchange) • GAAP EPS was $0.60 and Non-GAAP EPS was $1.80; Includes Net Impact of $(0.09) Per Share for ...